The management of thyroid nodules has moved decisively toward avoiding overtreatment — both overdiagnosis and overly aggressive surgery. On the diagnostic side, ultrasound risk-stratification systems (TI-RADS) reduce unnecessary biopsies, fine-needle aspiration is interpreted through the Bethesda system, and molecular testing of indeterminate cytology further refines malignancy risk, sparing many patients diagnostic surgery. On the management side, active surveillance is now accepted for low-risk nodules and small papillary microcarcinomas, and lobectomy is increasingly favored over total thyroidectomy for small, isolated cancers.
The most notable procedural shift is the rise of minimally invasive thermal ablation — radiofrequency, laser, and microwave ablation — for benign nodules causing compressive or cosmetic symptoms, offering symptom relief without surgery or lifelong thyroid hormone replacement; these techniques are also being studied for selected low-risk papillary microcarcinomas. Radioiodine remains effective for reducing the size of toxic multinodular goitre.
Further reading: contemporary thyroid nodule management (Kobaly et al., Annual Review of Medicine 2022; Alexander et al., Lancet Diabetes & Endocrinology 2022); nonsurgical ablative therapies (Stan et al., 2022).